Skip to content
DataLookout
Menu

NCT07278856

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Mar 31, 2027 to Dec 10, 2027
    • Eligibility criteria expanded, about 68 words
    • Secondary endpoints: details revised at 3 of 8 entries
    • Study description revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 27, 2026 to Dec 16, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Maximum tolerated dose (MTD) of ruxolitinib when given in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy
Timeframe: Prior to cycle 2 day 1 (cycle length = 21 days)
Incidence of adverse events
Timeframe: Up to 30 days after last dose of treatment

Secondary (8)

Rate of ruxolitinib discontinuation due to toxicity while receiving ruxolitinib with CHOP therapy (Part A)
Complete response (CR) rate (Part A)
Overall response rate (Part A)
Patient-reported outcomes (Part A)
Rate of ruxolitinib discontinuation due to toxicity while receiving ruxolitinib maintenance monotherapy following ruxolitinib with CHOP (Part B)
Show 3 moreShow less
Rate of conversion from partial response to CR (Part B)
Patient-reported outcomes (Part B) PROMIS
Patient-reported outcomes (Part B) FACT-Item GP5

Arms and interventions

Treatment (ruxolitinib, CHOP)Experimental

See Detailed Description

Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography, Multigated Acquisition Scan

Drugs: Cyclophosphamide, Doxorubicin, Prednisone, Ruxolitinib Phosphate, Vincristine

Biologicals: Filgrastim, Pegfilgrastim

Other: Fludeoxyglucose F-18, Questionnaire Administration

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States